Bright Minds Biosciences Inc.
DRUGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Valued at $504.0M, DRUG is a small-cap name in its sector. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Market Cap
$504.0M
Beta
0.23
P/E (TTM)
—
P/E (Fwd)
-8.85
EPS (TTM)
$-2.05
EPS (Fwd)
$-5.78
ROE
-13.6%
ROA
-13.5%
Cash
$307.8M
Total Debt
$65,589
Free CF
-$18.8M
52W Change
-13.1%
Annual Financials
Cash vs Debt
Where DRUG stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, DRUG finished 26.20% below its 150-day moving average ($73.24) and 28.58% below its 200-day moving average ($75.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DRUG overbought or oversold?
At the October 12, 2026 close, DRUG's RSI(14) was 38.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $307.8M in cash and $66K in debt, DRUG maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$18.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -13.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
DRUG's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, DRUG has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DRUG.